# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen initiates coverage on Axogen (NASDAQ:AXGN) with a Buy rating and announces Price Tar...
FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its fu...
Axogen, Inc. (NASDAQ:AXGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug ...
Axogen (NASDAQ:AXGN) narrows FY2025 sales outlook from $215.439 million-$219.185 million to $219.000 million vs $216.463 millio...
Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.06 by 93.55...